Knee Osteoarthritis After Menopause: What the Cartilage Research Shows

Why does knee osteoarthritis spike around menopause?

For most of adult life, knee osteoarthritis rates track fairly evenly between men and women. Somewhere in the mid-40s to mid-50s, the female rate pulls sharply ahead. By 64, a woman is about three times more likely than a man of the same age to have radiographic evidence of knee osteoarthritis.

That window, mid-40s to mid-50s, is also the median age of natural menopause. Researchers have circled the overlap for years. The 2026 meta-analysis was built specifically to test it.

Three things happen at roughly the same time in a woman's knees during that window. It's a short list, but each item is measurable on its own:

• Estrogen levels fall, often sharply, over one to three years.
• Cartilage and bone turnover markers rise, detectable in urine and blood.
• Reported joint pain and stiffness increase, independent of weight change.

None of those three facts alone proves causation. Together, they are why estrogen receptors in joint tissue became a real research question instead of a footnote.

The three-year window, not a slow decline

What makes this pattern different from ordinary aging is the speed. Most joint changes associated with aging unfold over decades. The estrogen drop at menopause is compressed into a much narrower window, and several of the biomarker changes tied to cartilage breakdown track that same compressed timeline rather than a gradual slope.

The symptoms women describe in that window tend to cluster in a specific way. It's worth naming them plainly:

• Morning stiffness that eases within 30 minutes of moving, rather than lasting all day.
• Aching that's worse after long stretches of sitting or standing still.
• A new grinding or catching sensation going up and down stairs.
• Swelling around the kneecap that wasn't there a year earlier.
• Pain that shows up on both knees around the same time, not just one.

What does estrogen actually do inside a joint?

Estrogen receptors are not limited to reproductive tissue. They sit inside chondrocytes, the cells that build and maintain cartilage, inside synovial cells lining the joint capsule, and inside the subchondral bone directly beneath the cartilage surface.

That distribution matters. Estrogen is not acting on the knee from a distance through some indirect hormonal cascade. It is present at the site, in the cells doing the actual work of maintaining joint tissue.

Three fronts, one joint

The mechanism researchers propose runs in three directions at once. Estrogen deficiency degrades the cartilage matrix directly. It disturbs the bone underneath the cartilage that normally absorbs and distributes joint load. And it removes a check on inflammatory signaling that would otherwise slow cartilage breakdown. A knee losing ground on all three fronts at the same time is a different situation than ordinary wear and tear from walking and standing.

What did the 2026 meta-analysis find?

The Tehalia et al. review pooled 11 studies, 6 in humans and 5 in animals, and the honest picture is a split one. It's worth reporting exactly as published rather than smoothing it into a cleaner story than the data supports.

In the animal studies, the signal was statistically significant. Histological cartilage degeneration was clearly worse in estrogen-deficient, or ovariectomized, animals than in controls (SMD -1.72, 95% CI -3.41 to -0.03, P = 0.047). Ovariectomized animals also showed 25 to 40% reduced bone mineral density at the joint.

In the human studies, the same direction of effect showed up but did not reach statistical significance. The pooled studies were small and varied widely in methodology, which widens confidence intervals fast. Postmenopausal women showed roughly 15% greater loss of cartilage thickness than premenopausal women on MRI, and markers of cartilage breakdown trended higher, but the authors could not rule out chance.

Why animal data is cleaner than human data here

Ovariectomized rats are easy to study with tight controls. Same age, same diet, same surgical timing, same measurement protocol. Postmenopausal women are not. Every study in the pooled human data measured something slightly different, at a different point after menopause, with a different imaging protocol, and pooling that kind of variation makes statistical significance hard to reach even when the underlying direction of effect is real. The direction of the evidence points one way. The statistical confidence in humans is not there yet, and that gap is worth sitting with rather than glossing over.

Does hormone therapy change the numbers?

The same body of research includes an observational finding worth stating plainly. Women using hormone replacement therapy showed a 30% lower prevalence of knee osteoarthritis than non-users (odds ratio 0.70) in the pooled studies. Separately, estrogen replacement has been shown to increase chondrocyte synthesis of proteoglycans and IGFBP-2, the same building blocks described in the mechanism table above.

This is association data from observational studies, not a randomized controlled trial built to test whether HRT prevents osteoarthritis. It is consistent with the mechanism. It does not prove the mechanism on its own, and it says nothing about what any individual woman should do, because hormone therapy carries its own risk and benefit calculation that belongs between her and her doctor.

What does shilajit's own research show for joints?

Shilajit's joint research runs on a separate track from the estrogen story above, and the two should not be blurred together.

The relevant mechanism is fulvic acid, which makes up 60 to 80% of shilajit's dry weight. In a study of human monocytes, fulvic acid reduced COX-2 expression and PGE2 secretion by blocking the NF-kB signaling pathway. COX-2 is the same inflammatory enzyme that ibuprofen and Celebrex are built to inhibit. That gives fulvic acid a real, cellular-level anti-inflammatory action in human cells, independent of any hormonal pathway.

In a 2018 animal study, shilajit reduced cartilage degeneration and synovitis in rats with induced knee osteoarthritis over a 21-day period. That is the only shilajit-specific knee study published, and it was conducted in rats.

Here is where the two research threads stand, side by side:

The gap that stays open

No published trial has given human knee osteoarthritis patients shilajit and measured the outcome directly. That gap shouldn't be papered over with animal data dressed up to answer a question it doesn't answer. What the two threads together represent is a coherent mechanistic case, estrogen loss disrupting joint maintenance on one side and fulvic acid's verified anti-inflammatory action on the other, not a completed clinical answer.

Cartilage has limited capacity to regenerate once it's worn down, in anyone, regardless of what's taken. The realistic target here is slowing further inflammatory-driven degeneration, not reversing damage that has already occurred.

Across every human clinical study conducted on shilajit, zero serious adverse events have been reported. Purity still varies enormously between products, so a few things are worth checking on any shilajit product before buying:

• Third-party lab testing for heavy metals, batch by batch, not a one-time certificate from years ago.
• A clearly stated country or region of origin rather than a vague "mountain sourced" claim.
• A resin or extract form with a stated fulvic acid percentage, not just "shilajit powder."
• A company willing to show the actual lab report, not just a badge or seal on the label.

Optimum Shilajit

If you want the fulvic acid and trace mineral profile behind the research above, sourced from the Altai mountains and tested for heavy metals on every batch, here is Optimum Shilajit.

See Optimum Shilajit